Ap19
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
1. KEY INFORMATION
|
Name of person dealing (Note 1) |
JPMorgan Asset Management |
|
Company dealt in |
AbbVie Inc. |
|
Class of relevant security to which the dealings being disclosed relate (Note 2) |
US$0.01 common stock |
|
Date of dealing |
03 April 2020 |
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
|
|
Long |
Short |
||||
|
|
Number |
|
(%) |
Number |
|
(%) |
|
(1) Relevant securities |
20,559,740* 1.39* |
3,126 0.00 |
||||
|
(2) Derivatives (other than options) |
31,076 0.00 |
249,766 0.02 |
||||
|
(3) Options and agreements to purchase/sell |
|
|
||||
|
Total |
20,590,816* 1.39* |
252,892 0.02 |
||||
*In addition to the dealings in section 2a, there is an increase in the holding of 432 common stock due to a transfer.
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)
|
Class of relevant security: |
Long |
Short |
||||
|
|
Number |
|
(%) |
Number |
|
(%) |
|
(1) Relevant securities |
|
|
||||
|
(2) Derivatives (other than options) |
|
|
||||
|
(3) Options and agreements to purchase/sell |
|
|
||||
|
Total |
|
|
||||
Ap20
1. DEALINGS (Note 4)
(a) Purchases and sales
|
Purchase/sale |
Number of relevant securities |
Price per unit (Note 5) |
|
Purchase Purchase Purchase Purchase Purchase
Sale Sale Sale Sale Sale |
2,394 58 26,700 77 29
36 6 581 104,387 297 |
72.6263 USD 73.1800 USD 73.3639 USD 73.3700 USD 74.8414 USD
72.8060 USD 72.8070 USD 73.3148 USD 73.3571 USD 74.7606 USD |
(b) Derivatives transactions (other than options transactions)
|
Product name, e.g. CFD |
Nature of transaction (Note 6) |
Number of relevant securities (Note 7) |
Price per unit (Note 5) |
|
|
|
|
|
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
|
Product name, e.g. call option |
Writing, selling, purchasing, varying etc. |
Number of securities to which the option relates (Note 7) |
Exercise price |
Type, e.g. American, European etc. |
Expiry date |
Option money paid/received per unit (Note 5) |
|
|
|
|
|
|
|
|
(ii) Exercising
|
Product name, e.g. call option |
Number of securities |
Exercise price per unit (Note 5) |
|
|
|
|
(d) Other dealings (including transactions in respect of new securities) (Note 4)
|
Nature of transaction (Note 8) |
Details |
Price per unit (if applicable) (Note 5) |
|
|
|
|
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any
relevant securities to which any derivative referred to on this form is referenced. If none, this
should be stated.
Is a Supplemental Form 8 attached? (Note 9) NO
|
Date of disclosure |
06 April 2020 |
|
Contact name |
Daniel Swart |
|
Telephone number |
0207 134 6168 |
|
If a connected EFM, name of offeree/offeror with which connected |
Allergan plc |
|
If a connected EFM, state nature of connection (Note 10) |
Financial Advisor to Allergan plc |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
